Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)
16.81
-0.10 (-0.59%)
Apr 29, 2026, 3:04 PM CST
SHE:002393 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,351 | 1,389 | 1,332 | 1,145 | 1,141 | 1,087 |
Other Revenue | 3.36 | 3.36 | 4.01 | 7.7 | 6.05 | 4.67 |
| 1,354 | 1,392 | 1,336 | 1,153 | 1,147 | 1,092 | |
Revenue Growth (YoY) | 0.99% | 4.18% | 15.88% | 0.56% | 5.00% | -4.29% |
Cost of Revenue | 638.13 | 644.93 | 624.04 | 487.97 | 510.51 | 473.95 |
Gross Profit | 716.32 | 747.08 | 712.11 | 665.06 | 636.08 | 618 |
Selling, General & Admin | 485.5 | 520.47 | 500.39 | 424.61 | 448.45 | 466.29 |
Research & Development | 102.15 | 112.93 | 122.1 | 102.48 | 102.26 | 100.82 |
Other Operating Expenses | 20.17 | 20.62 | 20.19 | 19.64 | 24.1 | 22.33 |
Operating Expenses | 607.43 | 653.62 | 642.7 | 546.47 | 575.03 | 589.34 |
Operating Income | 108.89 | 93.46 | 69.41 | 118.6 | 61.05 | 28.66 |
Interest Expense | -2.25 | -2.25 | -2.66 | -0.75 | -0.88 | -0.32 |
Interest & Investment Income | 378.51 | 376.29 | 147.31 | 76.03 | 91.93 | 106.85 |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | 0.01 | 0.01 | 0.11 | -0.06 |
Other Non Operating Income (Expenses) | -23.25 | -0.16 | -0.7 | 2.23 | -2.16 | -0.18 |
EBT Excluding Unusual Items | 461.87 | 467.32 | 213.37 | 196.12 | 150.05 | 134.95 |
Merger & Restructuring Charges | - | - | - | -4.99 | - | - |
Gain (Loss) on Sale of Investments | 2.45 | 2.11 | 2.9 | 0.62 | 0.28 | - |
Gain (Loss) on Sale of Assets | 0.3 | 0.25 | -0.1 | 238.7 | -34.82 | - |
Asset Writedown | -4.08 | -4.08 | -0.3 | -15.27 | -1.2 | -1.61 |
Other Unusual Items | -9.99 | -9.99 | 0.07 | 5.02 | 4.05 | 3.78 |
Pretax Income | 450.55 | 455.61 | 215.95 | 420.21 | 118.36 | 137.12 |
Income Tax Expense | 31.33 | 32.88 | 29.99 | 58.39 | 24.76 | 15.01 |
Earnings From Continuing Operations | 419.22 | 422.73 | 185.96 | 361.83 | 93.61 | 122.11 |
Minority Interest in Earnings | -6.33 | -6.44 | -1.43 | - | - | - |
Net Income | 412.89 | 416.28 | 184.53 | 361.83 | 93.61 | 122.11 |
Net Income to Common | 412.89 | 416.28 | 184.53 | 361.83 | 93.61 | 122.11 |
Net Income Growth | 128.56% | 125.59% | -49.00% | 286.54% | -23.34% | 1317.31% |
Shares Outstanding (Basic) | 307 | 308 | 308 | 310 | 308 | 306 |
Shares Outstanding (Diluted) | 307 | 308 | 308 | 310 | 308 | 306 |
Shares Change (YoY) | -0.70% | 0.26% | -0.83% | 0.59% | 0.70% | 5.91% |
EPS (Basic) | 1.34 | 1.35 | 0.60 | 1.17 | 0.30 | 0.40 |
EPS (Diluted) | 1.34 | 1.35 | 0.60 | 1.17 | 0.30 | 0.40 |
EPS Growth | 130.17% | 125.00% | -48.57% | 284.29% | -23.87% | 1238.26% |
Free Cash Flow | 214.7 | 210.04 | 34.51 | 138.29 | 290.47 | 108.1 |
Free Cash Flow Per Share | 0.70 | 0.68 | 0.11 | 0.45 | 0.94 | 0.35 |
Dividend Per Share | 0.750 | 0.750 | 0.292 | 0.357 | 0.179 | 0.179 |
Dividend Growth | 157.11% | 157.11% | -18.31% | 99.94% | - | 200.17% |
Gross Margin | 52.89% | 53.67% | 53.30% | 57.68% | 55.48% | 56.60% |
Operating Margin | 8.04% | 6.71% | 5.20% | 10.29% | 5.32% | 2.62% |
Profit Margin | 30.48% | 29.90% | 13.81% | 31.38% | 8.16% | 11.18% |
Free Cash Flow Margin | 15.85% | 15.09% | 2.58% | 11.99% | 25.33% | 9.90% |
EBITDA | 181.28 | 167.03 | 147.7 | 185.03 | 126.25 | 87.94 |
EBITDA Margin | 13.38% | 12.00% | 11.05% | 16.05% | 11.01% | 8.05% |
D&A For EBITDA | 72.39 | 73.57 | 78.29 | 66.43 | 65.2 | 59.28 |
EBIT | 108.89 | 93.46 | 69.41 | 118.6 | 61.05 | 28.66 |
EBIT Margin | 8.04% | 6.71% | 5.20% | 10.29% | 5.32% | 2.62% |
Effective Tax Rate | 6.95% | 7.22% | 13.89% | 13.89% | 20.92% | 10.95% |
Revenue as Reported | 1,392 | 1,392 | 1,336 | 1,153 | 1,147 | 1,092 |
Advertising Expenses | - | 247.48 | 266.99 | 253.43 | 264.36 | 283.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.